Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion

Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion

BackgroundHepatic arterial infusion (HAI) of oxaliplatin, leucovorin, and fluorouracil (FOLFOX) plus sorafenib has a more desirable effect versus sorafenib for hepatocellular carcinoma (HCC) patients with portal vein invasion. However, considering the high cost of hepatic arterial infusion of chemot...

Full description

Bibliographic Details
Main Authors: Meiyue Li, Shen Lin, Leslie Wilson, Pinfang Huang, Hang Wang, Shubin Lai, Liangliang Dong, Xiongwei Xu, Xiuhua Weng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
cost-effectiveness analysis
hepatocellular carcinoma
combination therapy
sorafenib
hepatic arterial infusion chemotherapy
FOLFOX
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.562135/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.562135/full

Similar Items